Patents by Inventor Thomas Patrick BEYER

Thomas Patrick BEYER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL RNA THERAPEUTICS AND USES THEREOF
    Publication number: 20260209772
    Abstract: The present disclosure relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the HMGCR receptor (expressed by the HMGCR gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases and disorders involving the regulation of HMGCR expression and function, such as diseases and disorders that are risk factors for ASCVD (such as, dyslipidemia, such as hypercholesteremia).
    Type: Application
    Filed: December 22, 2023
    Publication date: July 23, 2026
    Inventors: Patrick Joseph ANTONELLIS, Thomas Patrick BEYER, Jean Mawuena BRANTTIE, Christine Chih-Tao CHENG, Marjoke F. DEBETS, Konstantinos GAVARDINAS, Gregory Lawrence LACKNER, Jibo WANG, Takako WILSON
  • NOVEL RNA THERAPEUTICS AND USES THEREOF
    Publication number: 20250382615
    Abstract: The present invention relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the ANGPTL8 receptor (expressed by the ANGPTL8 gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases involving the regulation of ANGPTL8 expression and function, such as dyslipidemia, a cardiovascular disorder, or a cardiometabolic disorder.
    Type: Application
    Filed: December 22, 2023
    Publication date: December 18, 2025
    Inventors: Marijean EGGEN, Patrick Joseph ANTONELLIS, Seth Andrew BAWEL, Thomas Patrick BEYER, Christine Chih-Tao CHENG, Gregory Lawrence LACKNER, Rebecca Ruth MILES, Jibo WANG, Takako WILSON
  • NOVEL RNA THERAPEUTICS AND USES THEREOF
    Publication number: 20230022590
    Abstract: The present disclosure relates to novel RNAi agents designed to decrease the expression of ANGPTL8 in the liver, where the RNAi agents comprise delivery moieties conjugated to oligonucleotides optionally via a linker. The RNAi agents are useful in the treatment of diseases involving the regulation of ANGPTL8 expression.
    Type: Application
    Filed: June 22, 2022
    Publication date: January 26, 2023
    Inventors: Rebecca Ruth MILES, Jibo WANG, Melissa Ann BELLINGER, Thomas Patrick BEYER, Christine Chih-Tao CHENG, MariJean EGGEN, Gregory Lawrence LACKNER